<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-114117" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Genetics, Philadelphia Chromosome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haider</surname>
            <given-names>Mobeen Z.</given-names>
          </name>
          <aff>King Edward Medical University, Lahore, Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anwer</surname>
            <given-names>Faiz</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mobeen Haider declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faiz Anwer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-114117.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Philadelphia chromosome (Ph), named after the city where it was first described, was described for the first time by Nowell and Hungerford in 1960, in two patients who had lost the long arm of chromosome 22.<xref ref-type="bibr" rid="article-114117.r1">[1]</xref><xref ref-type="bibr" rid="article-114117.r2">[2]</xref><xref ref-type="bibr" rid="article-114117.r3">[3]</xref> As the Giemsa staining improved over the decade, Rowley showed that this truncated chromosome was generated as a result of the translocation of the long arm of chromosomes 9 and 22.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref><xref ref-type="bibr" rid="article-114117.r3">[3]</xref><xref ref-type="bibr" rid="article-114117.r4">[4]</xref>&#x000a0;The presence of the abnormal Ph chromosome in cells of myeloid, megakaryocytic, along with erythroid lineages pointed to the origination of the disorder in a pluripotential stem cell.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref>&#x000a0;Philadelphia chromosome is the hallmark of chronic myeloid leukemia (CML)&#x000a0;along with some other leukemias including acute lymphoblastic leukemia (ALL) (mostly B cell ALL, rarely T cell ALL),&#x000a0;acute myeloid leukemia (AML), chronic neutrophilic leukemia (CNL), and mixed phenotype acute leukemia (MPAL).<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r5">[5]</xref><xref ref-type="bibr" rid="article-114117.r6">[6]</xref><xref ref-type="bibr" rid="article-114117.r7">[7]</xref><xref ref-type="bibr" rid="article-114117.r8">[8]</xref><xref ref-type="bibr" rid="article-114117.r9">[9]</xref><xref ref-type="bibr" rid="article-114117.r10">[10]</xref><xref ref-type="bibr" rid="article-114117.r11">[11]</xref></p>
      </sec>
      <sec id="article-114117.s2" sec-type="Development">
        <title>Development</title>
        <p>The Philadelphia chromosome is generated when the proto-oncogene Abelson murine leukemia (ABL1)&#x000a0; gene, located on the band q34 on chromosome 9, translocates to the band q11 on chromosome 22 where the breakpoint cluster gene (BCR) is.<xref ref-type="bibr" rid="article-114117.r8">[8]</xref><xref ref-type="bibr" rid="article-114117.r12">[12]</xref>&#x000a0;The translocation t(9;22)(q34;q11) results in the formation of a fusion gene called BCR-ABL1.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
      </sec>
      <sec id="article-114117.s3" sec-type="Biochemical">
        <title>Biochemical</title>
        <p>The domains from BCR include:</p>
        <list list-type="order">
          <list-item>
            <p>CC domain</p>
          </list-item>
          <list-item>
            <p>Ser/Thr kinase domain (contains a docking site Y177)</p>
          </list-item>
          <list-item>
            <p>Rho/GEF kinase domain</p>
          </list-item>
        </list>
        <p>The domains from ABL1 include:</p>
        <list list-type="order">
          <list-item>
            <p>SH domain (SH1/SH2)</p>
          </list-item>
          <list-item>
            <p>Proline-rich domain</p>
          </list-item>
          <list-item>
            <p>DNA &#x00026; actin-binding domains</p>
          </list-item>
        </list>
        <p>The CC domain and Y177 of BCR are essential for the activation of the ABL1 gene and have shown to be closely associated with sensitivity to tyrosine kinase inhibitor (TKI). The Rho/GEF kinase domain plays a vital role in activating differentiation in the protooncogene induced leukemogenesis.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r13">[13]</xref></p>
        <p>The SH domain of ABL1 controls the gene&#x02019;s activation and deactivation, and hence this domain is an important site for pharmacologic intervention.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
        <p>As a result of different breakpoints in the BCR gene, that occur over quite a short DNA stretch of 5 -6 kilobases in the middle of the gene, three different BCR/ABL1 proteins are formed namely P190, P210, P230 which are usually associated with ALL, CML and CNL respectively. The numeral value represents the kDa size of the hybrid protein.&#x000a0;There have been some reports showing correlations of P190 with CML, P210 with ALL, and P190 or P210 with AML. P230is formed by the fusion of the ABL1 gene with almost the entire BCR gene leading to the production of a 230-kDa protein.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref>&#x000a0;It is the molecular diagnostic marker for neutrophilic-chronic myeloid leukemia (CML-N).<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r9">[9]</xref> &#x000a0;</p>
        <p>In CML, the oncoprotein P210 forms by the fusion of exon 2 (b2) or exon 3 (b3) of the BCR gene with the exon 2 (a2) of the ABL1 gene leading to the formation of either b2a2 or b3a2 11345193. Both of the transcripts produce a hybrid P210.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-114117.s4" sec-type="Function">
        <title>Function</title>
        <p>The normal ABL Tyrosine Kinase (TK) is responsible for the activation of signal pathways that lead to increased proliferation, better viability, and changed migration as well as homing. Normally these pathways are under close regulation by different hematopoietic growth factors.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref>&#x000a0;The ABL1 protein is a non-receptor tyrosine kinase, and it exists throughout the hematopoietic development, however myeloid maturation results in its declining levels.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref> The normal BCR gene is responsible for the oxidative burst in neutrophils.</p>
      </sec>
      <sec id="article-114117.s5" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>The generation of BCR/ABL1 results in the constitutive activation of tyrosine kinase. It results in continued cell proliferation, inhibiting cell differentiation, and cell death. There are numerous pathways associated with the pathogenesis of BCR-ABL1 gene, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>JAK2/STAT pathway:</bold> The activation of Janus Kinase (JAK) and Signal Transducers and Activation of Transcription (STAT) has been reported in P190 and P210positive leukemias. The JAK2/STAT activation in BCR/ABL1 leads to uncontrolled cell growth as well as cell survival.<xref ref-type="bibr" rid="article-114117.r14">[14]</xref><xref ref-type="bibr" rid="article-114117.r15">[15]</xref><xref ref-type="bibr" rid="article-114117.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>PI3K</bold><bold>-</bold><bold>AKT</bold><bold>-</bold><bold>mTOR pathway</bold>: The PI3K-AKT-mammalian target of the rapamycin (mTOR) pathway activates the c-kit positive hematopoietic stem cells; this leads to a proliferative state in CML.<xref ref-type="bibr" rid="article-114117.r17">[17]</xref> This pathway controls cell survival, proliferation, cell cycle arrest, and has gained importance for pharmacological intervention over the past decade.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p><bold>MAPK/ERK (RAS/RAF/MEK/ERK) pathway</bold>: This pathway is involved in signal transmission from cell surface receptors to nuclear factors involved in transcription. Osteopontin (OPN), which overexpresses in BCR/ABL1, uses this pathway to maintain a leukemic microenvironment. It, in turn, promotes and maintains the proliferation and survival of leukemic cells as well as plays a role in cell differentiation and apoptosis.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r18">[18]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>TRAIL-induced apoptosis</bold>: Tumor necrosis factor (TNF)- related apoptosis-inducing ligand- TNFSF10 (TRAIL) is a death receptor ligand that normally plays a role in apoptosis. BCR/ABL1 oncogene results in the downregulation of TRAIL, hence leading to decreased apoptosis.<xref ref-type="bibr" rid="article-114117.r19">[19]</xref><xref ref-type="bibr" rid="article-114117.r20">[20]</xref><xref ref-type="bibr" rid="article-114117.r21">[21]</xref><xref ref-type="bibr" rid="article-114117.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><bold>C/EBP</bold>
<bold>-mediated differentiation</bold>: CCAAT/enhancer-binding proteins (C/EBPs) are a type of transcription factors that are involved in the regulation of normal maturation of common myeloid cells to granulocyte-monocyte progenitor cells. This pathway is suppressed by the BCR/ABL1 oncogene.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r22">[22]</xref></p>
          </list-item>
        </list>
        <p><bold><italic toggle="yes">CONCURRENT GENETIC ABNORMALITIES</italic></bold>:</p>
        <p>In addition to the leukemogenic effect, evidence suggests that BCR/ABL1 oncogene independently leads to genomic instability.<xref ref-type="bibr" rid="article-114117.r23">[23]</xref> A recent study has shown that several genes that predominantly play a role in the proliferation and differentiation of hematopoietic stem cells are upregulated in BCR/ABL positive CML.<xref ref-type="bibr" rid="article-114117.r24">[24]</xref></p>
        <p>Common genes that are reportedly deleted in Philadelphia positive leukemias include</p>
        <list list-type="bullet">
          <list-item>
            <p>IKZF1 (7q12.2)&#x000a0;<xref ref-type="bibr" rid="article-114117.r25">[25]</xref> &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>PAX5 (9p13)&#x000a0;<xref ref-type="bibr" rid="article-114117.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>EBF1 (5q34)&#x000a0;&#x000a0;<xref ref-type="bibr" rid="article-114117.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>CDKN2A/B (9p13-p23.1)&#x000a0;<xref ref-type="bibr" rid="article-114117.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>IG (14q32.33)&#x000a0;<xref ref-type="bibr" rid="article-114117.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>TCR (14q11.2)&#x000a0;<xref ref-type="bibr" rid="article-114117.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>BTG1 (12q21.33)&#x000a0;<xref ref-type="bibr" rid="article-114117.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>Studies have shown that primary or acquired resistance to treatment as well as relapse, can be attributed to different mutations. Rearrangements in the BCR gene can help in the prediction of response to therapy.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
      </sec>
      <sec id="article-114117.s6" sec-type="Testing">
        <title>Testing</title>
        <p>Philadelphia chromosome is detectable with cytogenetic testing, or a reverse transcriptase PCR test can demonstrate the BCR/ABL transcripts.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref>&#x000a0;Along with a quantitative PCR for BCR/ABL1, flow cytometry is also necessary to determine the lineage. As mentioned before, the patients usually have a concurrent genetic abnormality, so it is reasonable to get a mutational analysis done.<xref ref-type="bibr" rid="article-114117.r30">[30]</xref><xref ref-type="bibr" rid="article-114117.r31">[31]</xref>&#x000a0;In addition to the above testing, liver function tests, as well as renal function tests, should be performed.<xref ref-type="bibr" rid="article-114117.r30">[30]</xref></p>
      </sec>
      <sec id="article-114117.s7" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>This oncogene leads to constitutive activation of tyrosine kinase, which is responsible for more proliferation and better viability of the myeloid lineage cells.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref> The translocation results in decreased requirements for growth factors and provides freedom from their regulatory control.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref> This oncogene also affects cellular differentiation and apoptosis.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
      </sec>
      <sec id="article-114117.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>In addition to CML, Philadelphia chromosome has shown an association with different leukemias including</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute Myeloid Leukemia (AML)&#x000a0;<xref ref-type="bibr" rid="article-114117.r4">[4]</xref><xref ref-type="bibr" rid="article-114117.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Acute Lymphoblastic Leukemia (ALL)&#x000a0; (mostly B cell ALL, rarely T cell ALL) <xref ref-type="bibr" rid="article-114117.r6">[6]</xref><xref ref-type="bibr" rid="article-114117.r7">[7]</xref><xref ref-type="bibr" rid="article-114117.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic Neutrophilic Leukemia (CNL)&#x000a0;<xref ref-type="bibr" rid="article-114117.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Mixed Phenotype Acute Leukemia (MPAL)&#x000a0;<xref ref-type="bibr" rid="article-114117.r10">[10]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>There have been reports of detection of the chromosomal abnormality rarely in normal healthy people.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref>&#x000a0;Recently, a Philadelphia like ALL (Ph-like ALL) has been identified, which lacks the novel BCR-ABL1 translocation.<xref ref-type="bibr" rid="article-114117.r32">[32]</xref></p>
        <p><bold>CML:</bold>&#x000a0;The Ph chromosome is the diagnostic feature of CML. CML has an incidence of 50 per million per year and accounts for approximately 7 to 15% of the leukemias in the adult population.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref><xref ref-type="bibr" rid="article-114117.r33">[33]</xref>&#x000a0;</p>
        <p><bold>ALL:</bold> Philadelphia chromosome has been detected in 11&#x000a0;to 29 % of patients with ALL, although it is rarer with a prevalence of 1 to 3% in childhood ALL.<xref ref-type="bibr" rid="article-114117.r34">[34]</xref><xref ref-type="bibr" rid="article-114117.r35">[35]</xref></p>
        <p><bold>AML:</bold> In patients with AML, the chromosomal abnormality has a reported incidence of less than 1.5%.<xref ref-type="bibr" rid="article-114117.r36">[36]</xref></p>
        <p><bold>MPAL:</bold> Data collected from patients diagnosed with MPAL shows that the Ph chromosome is the most frequent aberrant cytogenetic abnormality, which has led to the recognition of Ph+MPAL as a distinct disease entity with a prevalence of less than 1% of all acute leukemias.<xref ref-type="bibr" rid="article-114117.r37">[37]</xref></p>
        <p>
<bold>
<italic toggle="yes">THERAPEUTIC IMPLICATIONS:</italic>
</bold>
</p>
        <p>For CML, at the moment, many (five FDA approved) tyrosine kinase inhibitors, belonging to different generations, (TKI) are being used for the treatment. TKIs belonging to different generations are currently available. Frist generation TKI includes imatinib, and second-generation TKI includes bosutinib, dasatinib, and nilotinib. Third generation TKIs include ponatinib. For the chronic phase, TKI first and second-generation TKIs are included in the frontline treatments recommended.<xref ref-type="bibr" rid="article-114117.r30">[30]</xref><xref ref-type="bibr" rid="article-114117.r38">[38]</xref><xref ref-type="bibr" rid="article-114117.r39">[39]</xref><xref ref-type="bibr" rid="article-114117.r40">[40]</xref><xref ref-type="bibr" rid="article-114117.r41">[41]</xref></p>
        <p>In patients diagnosed with the chronic phase of CML, risk calculations are performed before initiation of therapy. For this purpose, two different scoring systems are used.<xref ref-type="bibr" rid="article-114117.r31">[31]</xref> One is the Sokal risk calculation, which requires the age of the patient, platelet count, the percentage of myeloblasts found in the peripheral blood and size of the spleen,&#x000a0;whereas the Hasford risk calculation utilizes the same variables as Sokal calculator except for the percentage of myeloblasts it uses the percentage of blasts, basophils, and eosinophils.<xref ref-type="bibr" rid="article-114117.r42">[42]</xref><xref ref-type="bibr" rid="article-114117.r43">[43]</xref><xref ref-type="bibr" rid="article-114117.r42">[42]</xref>&#x000a0;For patients that have an intermediate or higher risk score, the recommendation is to consider the second-generation TKIs as the first line.<xref ref-type="bibr" rid="article-114117.r30">[30]</xref><xref ref-type="bibr" rid="article-114117.r40">[40]</xref><xref ref-type="bibr" rid="article-114117.r41">[41]</xref></p>
        <p>For patients with treatment failure or resistance to prior lines, the third generation TKI should be used.<xref ref-type="bibr" rid="article-114117.r44">[44]</xref> For patients with a disease that is refractory to the TKI therapy, a chemotherapeutic agent omacetaxine is also a recommendation.<xref ref-type="bibr" rid="article-114117.r30">[30]</xref><xref ref-type="bibr" rid="article-114117.r45">[45]</xref>&#x000a0;Studies have shown that primary or acquired resistance to treatment, as well as relapse, is attributable to different mutations. Rearrangements in the BCR gene can help in the prediction of response to therapy.</p>
        <p>For patients with Ph+ive ALL, in addition to TKI, concurrent use of chemotherapeutic agents has shown remarkable results. For patients who are refractory to the TKI therapy and for patients with Ph+ive MPAL, a combination of alternative or advanced generation TKIs, and hematopoietic stem cell transplantation are recommendations.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
        <p>
<bold>
<italic toggle="yes">PROGNOSTIC SIGNIFICANCE:</italic>
</bold>
</p>
        <p>The status of the Philadelphia chromosome is associated with substantially different prognoses in patients of different leukemic phenotypes. The presence of the Ph chromosome has also correlated with a higher risk of concurrent genomic abnormalities.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
        <p>In patients of CML, the location of the breakpoint in the BCR gene has shown an important association with prognosis. CML patients with a double Philadelphia chromosome are associated with a worse prognosis than those with a single Philadelphia chromosome.<xref ref-type="bibr" rid="article-114117.r46">[46]</xref>&#x000a0;The presence of concurrent genetic abnormalities is associated with a worse prognosis than in the blastic phase of CML.<xref ref-type="bibr" rid="article-114117.r2">[2]</xref></p>
        <p>ALL patients, both adults, as well as children who are Ph+ive, have shown a poor prognosis in comparison to those who are Ph -ive.<xref ref-type="bibr" rid="article-114117.r8">[8]</xref></p>
        <p>Patients with Ph+ive MPAL have shown a worse outcome in comparison to other leukemic phenotypes.<xref ref-type="bibr" rid="article-114117.r4">[4]</xref></p>
      </sec>
      <sec id="article-114117.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=114117&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=114117">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/114117/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=114117">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-114117.s10">
        <title>References</title>
        <ref id="article-114117.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NOWELL</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>HUNGERFORD</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Chromosome studies on normal and leukemic human leukocytes.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1960</year>
            <month>Jul</month>
            <volume>25</volume>
            <fpage>85</fpage>
            <page-range>85-109</page-range>
            <pub-id pub-id-type="pmid">14427847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sattler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of transformation by the BCR/ABL oncogene.</article-title>
            <source>Int J Hematol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>278</fpage>
            <page-range>278-91</page-range>
            <pub-id pub-id-type="pmid">11345193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowley</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Genetics. A story of swapped ends.</article-title>
            <source>Science</source>
            <year>2013</year>
            <month>Jun</month>
            <day>21</day>
            <volume>340</volume>
            <issue>6139</issue>
            <fpage>1412</fpage>
            <page-range>1412-3</page-range>
            <pub-id pub-id-type="pmid">23788787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>The Philadelphia chromosome in leukemogenesis.</article-title>
            <source>Chin J Cancer</source>
            <year>2016</year>
            <month>May</month>
            <day>27</day>
            <volume>35</volume>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">27233483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia.</article-title>
            <source>Med Oncol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>382</fpage>
            <pub-id pub-id-type="pmid">25428388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shtalrid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kloetzer</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Talpas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trujillo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Blick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutterman</surname>
                <given-names>JU</given-names>
              </name>
            </person-group>
            <article-title>A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.</article-title>
            <source>Nature</source>
            <year>1987</year>
            <month>Feb</month>
            <day>12-18</day>
            <volume>325</volume>
            <issue>6105</issue>
            <fpage>631</fpage>
            <page-range>631-5</page-range>
            <pub-id pub-id-type="pmid">3543692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verrma</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Vinod</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Dubashi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ariga</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Philadelphia chromosome positive pre-T cell acute lymphoblastic leukemia: a rare case report and short review.</article-title>
            <source>Indian J Hematol Blood Transfus</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>Suppl 1</issue>
            <fpage>177</fpage>
            <page-range>177-9</page-range>
            <pub-id pub-id-type="pmid">25332571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Advani</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pendergast</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Bcr-Abl variants: biological and clinical aspects.</article-title>
            <source>Leuk Res</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>713</fpage>
            <page-range>713-20</page-range>
            <pub-id pub-id-type="pmid">12191565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frigeri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sindona</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luciano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meloni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saglio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvatore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rotoli</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction).</article-title>
            <source>Blood</source>
            <year>1996</year>
            <month>Oct</month>
            <day>01</day>
            <volume>88</volume>
            <issue>7</issue>
            <fpage>2410</fpage>
            <page-range>2410-4</page-range>
            <pub-id pub-id-type="pmid">8839830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matutes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pickl</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Van't Veer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swansbury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strobl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Attarbaschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hopfinger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bene</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Porwit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Orfao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lemez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schabath</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Mar</month>
            <day>17</day>
            <volume>117</volume>
            <issue>11</issue>
            <fpage>3163</fpage>
            <page-range>3163-71</page-range>
            <pub-id pub-id-type="pmid">21228332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Neriah</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Mes-Masson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.</article-title>
            <source>Science</source>
            <year>1986</year>
            <month>Jul</month>
            <day>11</day>
            <volume>233</volume>
            <issue>4760</issue>
            <fpage>212</fpage>
            <page-range>212-4</page-range>
            <pub-id pub-id-type="pmid">3460176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koretzky</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>The legacy of the Philadelphia chromosome.</article-title>
            <source>J Clin Invest</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>8</issue>
            <fpage>2030</fpage>
            <page-range>2030-2</page-range>
            <pub-id pub-id-type="pmid">17671635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.</article-title>
            <source>Cancer Res</source>
            <year>2007</year>
            <month>Jul</month>
            <day>15</day>
            <volume>67</volume>
            <issue>14</issue>
            <fpage>7045</fpage>
            <page-range>7045-53</page-range>
            <pub-id pub-id-type="pmid">17638918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Samanta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Arlinghaus</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.</article-title>
            <source>Oncogene</source>
            <year>2008</year>
            <month>May</month>
            <day>15</day>
            <volume>27</volume>
            <issue>22</issue>
            <fpage>3194</fpage>
            <page-range>3194-200</page-range>
            <pub-id pub-id-type="pmid">18071309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warsch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Walz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sexl</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Sep</month>
            <day>26</day>
            <volume>122</volume>
            <issue>13</issue>
            <fpage>2167</fpage>
            <page-range>2167-75</page-range>
            <pub-id pub-id-type="pmid">23926299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valent</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Targeting the JAK2-STAT5 pathway in CML.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Aug</month>
            <day>28</day>
            <volume>124</volume>
            <issue>9</issue>
            <fpage>1386</fpage>
            <page-range>1386-8</page-range>
            <pub-id pub-id-type="pmid">25170113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.</article-title>
            <source>Cancer Gene Ther</source>
            <year>2015</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>227</fpage>
            <page-range>227-37</page-range>
            <pub-id pub-id-type="pmid">25837664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enciso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendoza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pelayo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Normal vs. Malignant hematopoiesis: the complexity of acute leukemia through systems biology.</article-title>
            <source>Front Genet</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>290</fpage>
            <pub-id pub-id-type="pmid">26442108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuroda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Inukai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nemoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akahane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirose</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honna-Oshiro</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kagami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yagita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tauchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugita</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.</article-title>
            <source>Oncogene</source>
            <year>2013</year>
            <month>Mar</month>
            <day>28</day>
            <volume>32</volume>
            <issue>13</issue>
            <fpage>1670</fpage>
            <page-range>1670-81</page-range>
            <pub-id pub-id-type="pmid">22665066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asgary</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andreeff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Functional expression of TRAIL by lymphoid and myeloid tumour cells.</article-title>
            <source>Br J Haematol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>3</issue>
            <fpage>827</fpage>
            <page-range>827-32</page-range>
            <pub-id pub-id-type="pmid">10468881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>De Carvalho</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Zenteno</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Jacysyn</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sardinha</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Zanichelli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hamerschlak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Pagnano</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Calle</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amarante-Mendes</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.</article-title>
            <source>Cell Death Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <day>12</day>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>e3114</fpage>
            <pub-id pub-id-type="pmid">29022901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Iwasaki-Arai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fenyus</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dayaram</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Shigematsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Levantini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huettner</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lekstrom-Himes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Akashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tenen</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.</article-title>
            <source>Immunity</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>853</fpage>
            <page-range>853-63</page-range>
            <pub-id pub-id-type="pmid">15589173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilaria</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership.</article-title>
            <source>Leuk Res</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>971</fpage>
            <page-range>971-3</page-range>
            <pub-id pub-id-type="pmid">12363461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gucwa</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Esopi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gurel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Yegnasubramanian</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.</article-title>
            <source>Oncotarget</source>
            <year>2013</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-28</page-range>
            <pub-id pub-id-type="pmid">23651669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kannan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sloma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Babovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bulaeva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rabu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Loriaux</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Radich</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Erber</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Eaves</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Jan</month>
            <day>15</day>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>504</fpage>
            <page-range>504-15</page-range>
            <pub-id pub-id-type="pmid">25370416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nacheva</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Brazma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Howard-Reeves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chanalaris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gancheva</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Apostolova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valga&#x000f1;on</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazzullo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.</article-title>
            <source>BMC Genomics</source>
            <year>2010</year>
            <month>Jan</month>
            <day>18</day>
            <volume>11</volume>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">20082691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Goorha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radtke</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Coustan-Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Girtman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pounds</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Relling</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Shurtleff</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Downing</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.</article-title>
            <source>Nature</source>
            <year>2007</year>
            <month>Apr</month>
            <day>12</day>
            <volume>446</volume>
            <issue>7137</issue>
            <fpage>758</fpage>
            <page-range>758-64</page-range>
            <pub-id pub-id-type="pmid">17344859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nacheva</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Brazma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gancheva</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Howard-Reeves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linch</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Hills</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kottaridis</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Does BCR/ABL1 positive acute myeloid leukaemia exist?</article-title>
            <source>Br J Haematol</source>
            <year>2013</year>
            <month>May</month>
            <volume>161</volume>
            <issue>4</issue>
            <fpage>541</fpage>
            <page-range>541-50</page-range>
            <pub-id pub-id-type="pmid">23521501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.</article-title>
            <source>Cancer Genet</source>
            <year>2014</year>
            <month>May</month>
            <volume>207</volume>
            <issue>5</issue>
            <fpage>226</fpage>
            <page-range>226-30</page-range>
            <pub-id pub-id-type="pmid">24998463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Eden</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Coviello</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Myelogenous Leukemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">30285354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jabbour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.</article-title>
            <source>Am J Hematol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>442</fpage>
            <page-range>442-459</page-range>
            <pub-id pub-id-type="pmid">29411417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siddiqi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.</article-title>
            <source>Semin Hematol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-241</page-range>
            <pub-id pub-id-type="pmid">30502852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2015.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-29</page-range>
            <pub-id pub-id-type="pmid">25559415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schultz</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Pullen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sather</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Heerema</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rubnitz</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Raetz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Winick</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Gaynon</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Camitta</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Feb</month>
            <day>01</day>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>926</fpage>
            <page-range>926-35</page-range>
            <pub-id pub-id-type="pmid">17003380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pullarkat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Slovak</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kopecky</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Mar</month>
            <day>01</day>
            <volume>111</volume>
            <issue>5</issue>
            <fpage>2563</fpage>
            <page-range>2563-72</page-range>
            <pub-id pub-id-type="pmid">18156492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soupir</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Vergilio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dal Cin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muzikansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>642</fpage>
            <page-range>642-50</page-range>
            <pub-id pub-id-type="pmid">17369142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimizu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokohama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hatsumi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Handa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nojima</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.</article-title>
            <source>Eur J Haematol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-301</page-range>
            <pub-id pub-id-type="pmid">24750307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hehlmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lauseker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sau&#x000df;ele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pfirrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hossfeld</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Nerl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gratwohl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baerlocher</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Heim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;mmendorf</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Fabarius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haferlach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schlegelberger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jeromin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Proetel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kohlbrenner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Voskanyan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinaldetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seifarth</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Spie&#x000df;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Balleisen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goebeler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dengler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burchert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stegelmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hne</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lindemann</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Pfreundschuh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spiekermann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berdel</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beelen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wernli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlegel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schlag</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;mper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hebart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomalla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scheid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schafhausen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verbeek</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Eckart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gassmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pezzutto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schenk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brossart</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bildat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasford</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.</article-title>
            <source>Leukemia</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>2398</fpage>
            <page-range>2398-2406</page-range>
            <pub-id pub-id-type="pmid">28804124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Branford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mongay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ortmann</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Radich</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.</article-title>
            <source>Int J Hematol</source>
            <year>2014</year>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-24</page-range>
            <pub-id pub-id-type="pmid">24658916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Saglio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boqu&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Chuah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Casanova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bradley-Garelik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Manos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na&#x000ef;ve Chronic Myeloid Leukemia Patients Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>10</day>
            <volume>34</volume>
            <issue>20</issue>
            <fpage>2333</fpage>
            <page-range>2333-40</page-range>
            <pub-id pub-id-type="pmid">27217448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamae</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakaseko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohmine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shibayama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.</article-title>
            <source>Int J Hematol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-336</page-range>
            <pub-id pub-id-type="pmid">29076005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokal</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tso</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prognostic discrimination in "good-risk" chronic granulocytic leukemia.</article-title>
            <source>Blood</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-99</page-range>
            <pub-id pub-id-type="pmid">6584184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pfirrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hehlmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Alimena</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steegmann</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1998</year>
            <month>Jun</month>
            <day>03</day>
            <volume>90</volume>
            <issue>11</issue>
            <fpage>850</fpage>
            <page-range>850-8</page-range>
            <pub-id pub-id-type="pmid">9625174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hjorth-Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>JJWM</given-names>
              </name>
              <name>
                <surname>Milojkovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>120</volume>
            <fpage>52</fpage>
            <page-range>52-59</page-range>
            <pub-id pub-id-type="pmid">29198338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoury</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wetzler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masszi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Digumarti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benichou</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Akard</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>120</fpage>
            <page-range>120-7</page-range>
            <pub-id pub-id-type="pmid">24650054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-114117.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Talpaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Cork</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCredie</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Freireich</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.</article-title>
            <source>Am J Med</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-54</page-range>
            <pub-id pub-id-type="pmid">3477958</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
